Society for Laboratory Automation and Screening (SLAS) 2018 conference
Expertise in automated, high-throughput qPCR, stem cell and gene editing solutions, and protein purification
The SLAS community promotes the synthesis of new technologies, partnerships, and ideas that advance laboratory workflows. The SLAS 2018 conference, which took place February 3–7 in San Diego, CA, is an essential hub for a community of experts who are forging ahead to apply state-of-the-art technologies to find solutions for significant biological challenges in an interdisciplinary manner.
Adding to the body of expertise at SLAS 2018, Takara Bio offered attendees expert guidance, technologies, and services for advancing their qPCR, stem cell, gene editing, and protein discovery research. Our instruments, such as the SmartChip Real‑Time PCR System, and our Cellartis, Guide-it, and Capturem product portfolios provide researchers with novel screening tools that bring unparalleled consistency to automation and screening efforts.
We are excited to help you find the best solutions for your research! Learn about our featured products and services, and download our exhibitor tutorial slides and poster presentations below.
Exhibitor tutorials at SLAS 2018
Flexible, high-throughput qPCR for genotyping and gene expression analysis using the SmartChip Real‑Time PCR System
In this Exhibitor Tutorial, we present multiple gene expression and genotyping studies that demonstrate the reliability and flexibility of the SmartChip Real‑Time PCR System. This quantitative PCR platform combines the high-throughput nature of microarrays with the sensitivity, precision, and dynamic range of quantitative real-time PCR. The power of the SmartChip system is derived from the 5,184 individual nanowells included in each chip provided in the SmartChip MyDesign Kit. The chips can be configured with 14 different assay and sample arrangements, allowing you to run the experiments you want instead of limiting them to rigid sample and assay formats. The SmartChip system utilizes 100-nl reactions with only 3–10 ng/µl of input required per reaction, which provides: 1) the sensitivity needed to eliminate the preamplification step, and 2) significant reagent and cost savings over 25‑µl reactions in 384‑well plates. With the SmartChip system, you can seamlessly switch between dispensing assay reagents and samples into blank chips and dispensing samples into custom, preprinted chips—without the need for revalidation. Run experiments the way you want, while getting the accurate and consistent results you expect.
If you'd like to learn more, request a copy of the technical brochure.
Innovative CRISPR/Cas9 gene knockin and SNP-detection tools for establishing human iPSC-derived disease model lines for drug screening
The unique combination of precise, footprint-free editing using CRISPR/Cas9 and human induced pluripotent stem (hiPS) cells facilitates a new level of sophistication in generating disease models which allow for rapid advancement in the development of new therapeutics. While CRISPR/Cas9-based gene editing is an effective technique to obtain knockout mutations with high efficiency, knocking in longer genes or sequences (>200 bp) via homology directed repair (HDR) is difficult to complete successfully. Therefore, more sophisticated screening tools are required for these low-efficiency knockins so that researchers can easily identify the edited clonal cell lines containing the engineered sequence.
One of the most powerful applications of genome editing is the introduction of base changes at specific genomic sites, resulting in sequences that mimic single-nucleotide polymorphisms (SNPs) related to human diseases or contain stop codons which generate gene knockouts. However, screening large numbers of clones to identify edited clonal cell lines containing the engineered base-of-interest is still a bottleneck, especially in the absence of a phenotypic readout.
To address this need, we developed a simple, high-throughput SNP-detection method that allows for rapid screening of clones from 96‑well plates and detection of edited clonal cell lines independent of the engineered nucleotide substitution and the surrounding targeted genomic loci. As a proof-of-concept, we applied this method to successfully detect all of the possible transitions in several human gene loci using genomic DNA as template or performed directly in cultured human fibroblasts. This screening method was then successfully used to screen hiPSCs clonal cell lines for SNPs related to tyrosinemia that were generated using CRISPR/Cas9.
Poster presentations at SLAS 2018
SLAS 2018 track: cellular technologies
A novel maintenance medium extends the lifespan and enables long-term applications for both human primary hepatocytes and human pluripotent stem cell-derived hepatocytes in conventional 2D cultures
Poster # 1250-E
Human primary hepatocytes are considered the gold standard for in vitro model systems of liver function for drug development, toxicity assessment, and metabolic disease research; however, their rapid loss of cell viability in conventional 2D culture limits their utility in these applications. Human induced pluripotent stem (hiPS) cell-derived hepatocytes have potential as a better in vitro model if they possess a relevant usage window and functionality—but this is challenging to accomplish.
Addressing these problems, our newly developed hepatocyte maintenance medium enables the culture of cryopreserved human primary hepatocytes or hiPS cell-derived hepatocytes for four or two weeks, respectively, with maintained viability and stable activities of several key cytochrome P450 enzymes (CYPs). Multiple analyses on cryopreserved hiPS cell-derived hepatocytes, including RT-qPCR, immunostainings, functional assays such as albumin secretion, and CYP activity assays demonstrate mature features and high functionality. Importantly, the hiPS cell-derived hepatocytes show expression of the essential genes of the drug-metabolizing machinery, such as CYPs, phase II enzymes, and transporters.
An extended in vitro culture time for hepatocytes enables chronic toxicity testing. We show that hiPS cell-derived hepatocytes can be exposed to known hepatotoxins for up to 14 days. Cells respond as expected to these toxic compounds, demonstrating their utility for chronic toxicity studies. The hiPS cell-derived hepatocytes also respond to insulin, and they can take up and store low-density lipoproteins and fatty acids.
The novel maintenance medium presented here maintains the viability and functionality of cryopreserved human primary hepatocytes and hiPS cell-derived hepatocytes from multiple lines for a much longer time than existing commercially available hepatocyte maintenance media. We hope that the increased assay window of functional hepatocytes in 2D cultures will empower new areas of liver research and applications.
SLAS 2018 track: assay development and screening
A fast and reliable method for detecting base editing in clonal cell lines
Poster # 1163-D
One of the most powerful applications of genome editing is the introduction of base changes in specific genomic sites to mimic single-nucleotide polymorphisms (SNPs) related to human diseases or introducing stop codons to generate precise gene knockouts. However, screening a large number of clones to identify edited clonal cell lines containing the engineered base of interest is still a bottleneck, especially if no phenotypic readout is applicable. Sanger sequencing is a potential approach to detect SNPs, but it is not easy to apply in a high-throughput manner; next-generation sequencing, in contrast, allows researchers to screen 96-well plates but at a far higher cost.
To address this need, we developed a simple SNP detection method that allows for rapid screening of clones from 96-well plates. Our assay comprises PCR amplification of the target site, followed by an enzymatic assay and a fluorescence-based readout using a standard plate reader. No additional special instrumentation is required. The overall workflow takes approximately four hours and any positive fluorescent signal is highly correlated with the successful introduction of the desired SNP. This method allows for the detection of edited clonal cell lines independent of the engineered nucleotide substitution and the surrounding targeted genomic loci. As a proof of concept, we have applied this method to successfully detect all possible transitions in several human loci using genomic DNA as template. As a final test, several nucleotide exchanges have been detected directly in cultured human fibroblasts.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2018 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.